Evaluation of the GreenScreen GADD45α-GFP indicator assay with non-proprietary and proprietary compounds

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 672, Issue 1, 2009, Pages 10-16

  Olaharski, Andrew ^a   Albertini, Silvio ^b   Kirchner, Stephan ^b   Platz, Stefan ^a   Uppal, Hirdesh ^a   Lin, Henry ^a   Kolaja, Kyle ^a  

^a ROCHE BIOSCIENCE   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Ames assay; Clastogen; Gadd45 ; Micronucleus assay; Mutagen; Rodent carcinogen

Indexed keywords

CARCINOGEN; GREEN FLUORESCENT PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45ALPHA; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; GADD45A PROTEIN, HUMAN; GADD45A PROTEIN, MOUSE; MUTAGENIC AGENT; NUCLEAR PROTEIN;

AMES TEST; ANIMAL CELL; ARTICLE; CARCINOGEN TESTING; CARCINOGENICITY; CHROMOSOME ABERRATION; CONTROLLED STUDY; GENOTOXICITY; MICRONUCLEUS TEST; MOUSE; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; SCREENING TEST; ANIMAL; BIOASSAY; BIOSYNTHESIS; CHEMISTRY; DRUG DESIGN; HUMAN; METABOLISM; METHODOLOGY; MUTAGEN TESTING; SENSITIVITY AND SPECIFICITY;

RODENTIA;

ANIMALS; BIOLOGICAL ASSAY; CARCINOGENS; CELL CYCLE PROTEINS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICRONUCLEUS TESTS; MUTAGENICITY TESTS; MUTAGENS; NUCLEAR PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 57649104877     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2008.08.019     Document Type: Article

References (24)

1. ICH Guidance for Industry. S2A Genotoxicity: Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals, S2A, 1996.
2. ICH Guidance for Industry. S2B Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals, S2B, 1997.
3. Muller L., Kikuchi Y., Probst G., Schechtman L., Shimada H., Sofuni T., and Tweats D. ICH-harmonised guidances on genotoxicity testing of pharmaceuticals: evolution, reasoning and impact. Mutat. Res. 436 (1999) 195-225
4. Kirkland D., Aardema M., Henderson L., and Muller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens. I. Sensitivity, specificity and relative predictivity. Mutat. Res. 584 (2005) 1-256
5. Hastwell P.W., Chai L.L., Roberts K.J., Webster T.W., Harvey J.S., Rees R.W., and Walmsley R.M. High-specificity and high-sensitivity genotoxicity assessment in a human cell line: validation of the GreenScreen HC GADD45a-GFP genotoxicity assay. Mutat. Res. 607 (2006) 160-175
6. Akerman G.S., Rosenzweig B.A., Domon O.E., McGarrity L.J., Blankenship L.R., Tsai C.A., Culp S.J., MacGregor J.T., Sistare F.D., Chen J.J., and Morris S.M. Gene expression profiles and genetic damage in benzo(a)pyrene diol epoxide-exposed TK6 cells. Mutat. Res. 549 (2004) 43-64
7. Arriola E.L., Lopez A.R., and Chresta C.M. Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. Oncogene 18 (1999) 1081-1091
8. Abbas T., Olivier M., Lopez J., Houser S., Xiao G., Kumar G.S., Tomasz M., and Bargonetti J. Differential activation of p53 by the various adducts of mitomycin C. J. Biol. Chem. 277 (2002) 40513-40519
9. Smith M.L., Kontny H.U., Zhan Q., Sreenath A., O'Connor P.M., and Fornace Jr. A.J. Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to u.v.-irradiation or cisplatin. Oncogene 13 (1996) 2255-2263
10. Aubrecht J., Narla R.K., Ghosh P., Stanek J., and Uckun F.M. Molecular genotoxicity profiles of apoptosis-inducing vanadocene complexes. Toxicol. Appl. Pharmacol. 154 (1999) 228-235
11. Ellinger-Ziegelbauer H., Stuart B., Wahle B., Bomann W., and Ahr H.J. Characteristic expression profiles induced by genotoxic carcinogens in rat liver. Toxicol. Sci. 77 (2004) 19-34
12. Ellinger-Ziegelbauer H., Stuart B., Wahle B., Bomann W., and Ahr H.J. Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. Mutat. Res. 575 (2005) 61-84
13. CCRIS TOXNET Database, Chemical Carcinogenesis Research Information System (CCRIS), 2007. http://www.toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?CCRIS.
14. Kirkland D., Aardema M., Muller L., and Makoto H. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens. II. Further analysis of mammalian cell results, relative predictivity and tumour profiles. Mutat. Res. 608 (2006) 29-42
15. GENETOX TOXNET Database, Genetic Toxicology Data Bank (GENE-TOX), 2007. http://www.toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?GENETOX.
16. FDA-CDER Pharmacology/Toxicology Review and Evaluation for Gefinitib (Iressa), NDA 21-399, 2002.
17. FDA-CDER Pharmacology/Toxicology Review and Evaluation for Sorafenib (Nexavar), NDA 21-913, 2005.
18. HL M. The generation of a unique machine description for chemical structures-a technique developed at chemical abstracts service. J. Chem. Doc. (1965) 107-113
19. Kado N.Y., Langley D., and Eisenstadt E. A simple modification of the Salmonella liquid-incubation assay. Increased sensitivity for detecting mutagens in human urine. Mutat. Res. 121 (1983) 25-32
20. Muster W., Albertini S., Chetelat A., Kirchner S., and Gocke E. A microsuspension screening version of the Ames test to predict the outcome of GLP assays for gene mutations. Environ. Mol. Mutagen. 35 Suppl. 31 (2000) 44
21. Kirchner S., Albertini S., Chetelat A., Gocke E., and Muster W. A microscale micronucleus test (MNT) in vitro screening assay with L5178Y TK+/- mouse lymphoma cells to predict the outcome of GLP-assays detecting clastogenic activity. Environ. Mol. Mutagen. 25 (2000) 35
22. Fenech M. The cytokinesis-block micronucleus technique: a detailed description of the method and its application to genotoxicity studies in human populations. Mutat. Res. 285 (1993) 35-44
23. Hartung T., Bremer S., Casati S., Coecke S., Corvi R., Fortaner S., Gribaldo L., Halder M., Hoffmann S., Roi A.J., Prieto P., Sabbioni E., Scott L., Worth A., and Zuang V. A modular approach to the ECVAM principles on test validity. Altern. Lab. Anim. 32 (2004) 467-472
24. Kirkland D., Pfuhler S., Tweats D., Aardema M., Corvi R., Darroudi F., Elhajouji A., Glatt H., Hastwell P., Hayashi M., Kasper P., Kirchner S., Lynch A., Marzin D., Maurici D., Meunier J.R., Muller L., Nohynek G., Parry J., Parry E., Thybaud V., Tice R., van Benthem J., Vanparys P., and White P. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: report of an ECVAM Workshop. Mutat. Res. 628 (2007) 31-55